COVID-19 Convalescent Plasma Program
C3PO Facilities VA CURES-1 Facilities
A world-renowned leader in infectious disease and transfusion medicine research, Vitalant Research Institute (VRI)—a division of Vitalant—is helping direct collection of blood plasma donations from recovered COVID-19 patients and developing technologies to detect and quantify virus-fighting antibodies. Recovered COVID-19 patients may have immune-boosting antibodies in their plasma; that plasma—called “convalescent plasma”—could be used to treat critically ill COVID-19 patients.
UPDATE! On Sunday, August 23, 2020, the U.S. Food and Drug Administration (FDA) issues an Emergency Use Authorization (EUA) for COVID-19 Convalescent Plasma (CCP) for the treatment of COVID-19 in hospitalized patients. Vitalant sent a communication to hospital partners on August 28, 2020 outlining what we know now about EUA impacts. View that communication
here.
We also shared information during a webinar on September 2, 2020. You can access a recording of this webinar
here, a copy of the powerpoint shared during the webinar (current as of September 9, 2020)
here and a Q&A resource (current as of September 9, 2020)
here.
ISBT Codes and Labels for customers who receive CCP units from Vitalant:
CCP Product Label Examples
The following codes are the original codes provided when CCP became available. It is high priority to verify these are entered in your system and this should be confirmation only.
Special testing codes, or modifiers, to differentiate low titer/high titer CCP products for the following codes:
- N0137: High titer for SARS-CoV-2 antibody
- N0138: Low titer for SARS-CoV-2 antibody
Apheresis CCP
| Description |
ISBT 128 Code |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|COVID-19 |
E9747V00*
Previously Provided |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<= -18C|Irradiated|COVID-19 |
E9753V00*
Previously Provided |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 |
E9752V00*
Previously Provided |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|1st container|COVID-19 |
E9754V00*
Previously Provided |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|2nd container|COVID-19 |
E9755V00*
Previously Provided |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|3rd container|COVID-19 |
E9756V00*
Previously Provided |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|4th container|COVID-19 |
E9757V00*
Previously Provided |
Label Example |
*Divided Code: VA0 - VE0
Whole Blood Derived CCP
| Description |
ISBT 128 Code |
Label Example |
| CONVALESCENT PLASMA|CP2D/XX/<=-18C|COVID-19 |
E9802V00
Previously Provided |
Label Example |
| CONVALESCENT PLASMA|CPD/XX/<=-18C|COVID-19 |
E9735V00
Previously Provided |
Label Example |
| CONVALESCENT PLASMA|CPDA-1/XX/<=-18C|COVID-19 |
E9804V00
Previously Provided |
Label Example |
Psoralen Treated CCP
| Description |
ISBT 128 Code |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Psoralen-treated|COVID-19 |
E9771V00*
Previously Provided |
|
*Divided Code: VA0 - VE0
The following codes were released by ICCBBA on November 6, 2020 to meet FDA EUA requirements for designating low and high titer CCP products.
Apheresis CCP (HIGH priority to enter)
| Description |
ISBT 128 Code |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|COVID-19 high titer |
EA160V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|COVID-19 low titer |
EA161V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|1st container|COVID-19 high titer |
EA166V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|1st container|COVID-19 low titer |
EA167V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|2nd container|COVID-19 high titer |
EA168V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|2nd container|COVID-19 low titer |
EA169V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|3rd container|COVID-19 high titer |
EA170V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|3rd container|COVID-19 low titer |
EA171V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|4th container|COVID-19 high titer |
EA172V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|4th container|COVID-19 low titer |
EA173V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|5th container|COVID-19 high titer |
EA296V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|5th container|COVID-19 low titer |
EA297V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 high titer |
EA162V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 low titer |
EA163V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|COVID-19 high titer |
EA182V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|COVID-19 low titer |
EA183V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|COVID-19 high titer |
EA184V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|COVID-19 low titer |
EA185V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|COVID-19 high titer |
EA186V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|COVID-19 low titer |
EA187V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|COVID-19 high titer |
EA188V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|COVID-19 low titer |
EA189V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|5th container|COVID-19 high titer |
EA298V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|5th container|COVID-19 low titer |
EA299V00* |
|
*Divided Code: VA0 - VE0
Whole Blood Derived CCP (HIGH priority to enter)
| Description |
ISBT 128 Code |
Label Example |
| CONVALESCENT PLASMA|CP2D/XX/<=-18C|COVID-19 high titer |
EA258V00 |
|
| CONVALESCENT PLASMA|CP2D/XX/<=-18C|COVID-19 low titer |
EA259V00 |
|
| CONVALESCENT PLASMA|CPDA-1/XX/<=-18C|COVID-19 high titer |
EA262V00 |
|
| CONVALESCENT PLASMA|CPDA-1/XX/<=-18C|COVID-19 low titer |
EA263V00 |
|
| Thawed CONVALESCENT PLASMA|CPD/XX/refg|COVID-19 high titer |
EA218V00 |
|
| Thawed CONVALESCENT PLASMA|CPD/XX/refg|COVID-19 low titer |
EA219V00 |
|
| Thawed CONVALESCENT PLASMA|CP2D/XX/refg|COVID-19 high titer |
EA260V00 |
|
| Thawed CONVALESCENT PLASMA|CP2D/XX/refg|COVID-19 low titer |
EA261V00 |
|
| Thawed CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 high titer |
EA276V00 |
|
| Thawed CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 low titer |
EA277V00 |
|
Psoralen Treated CCP (LOW priority to enter)
| Description |
ISBT 128 Code |
Label Example |
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Psoralen-treated|COVID-19 high titer |
EA200V00* |
|
| Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Psoralen-treated|COVID-19 low titer |
EA201V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Psoralen-treated|COVID-19 high titer |
EA234V00* |
|
| Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Psoralen-treated|COVID-19 low titer |
EA235V00* |
|
*Divided Code: VA0 - VE0
For customers recruiting potential CCP donors for qualification:
Donor Recruitment Flyer (English)
Donor Recruitment Flyer (Spanish)
Donor Recruitment Flyer Co-Branding Option (English)
Donor Recruitment Flyer Co-Branding Option (Spanish)
Click to download a PDF flyer to help recruit potential CCP donors.
Donor Recruitment Email/Letter Template
Click to download a Word document with suggested email/letter copy to help recruit potential CCP donors.
Donor Recruitment Social Media Copy
Click to download a Word document with suggested social media copy to help recruit potential CCP donors.
Social media graphics
Click to download graphics you can post on social media with the suggested copy.
| Instagram |
Twitter |
Facebook |
 |
.jpg.aspx?width=250&height=125 "1474_convalescent_tw_-(2).jpg") |
 |
Frequently Asked Questions about Vitalant's Convalescent Plasma Program
How does a current, contracted hospital customer obtain convalescent plasma from Vitalant?
Once a contracted customer has worked with their local contact(s) and taken the necessary steps to be part of Vitalant’s convalescent plasma program, they can take the following steps to order CCP.
- Please consent your patient to receive CCP as per your institutional policy. You may call Vitalant prior to the consent of the patient to obtain an estimated time of arrival of CCP to your facility. The consent is not needed prior to distribution of CCP to your facility but is needed prior to transfusion.
- Please provide the blood type of your patient to Vitalant if ABO-compatible plasma is requested.
- Please have your blood bank staff order CCP units through their online portal.
- Please inform Vitalant Hospital Services of the blood type of CCP needed, or if you can accept a non-compatible CCP unit for your patient. A Vitalant Transfusion Medicine MD is available for consultation regarding transfusing incompatible plasma.
- If an additional unit is needed for your patient, please have your blood bank staff order online or call Vitalant Hospital Services to order the additional unit.
- Please obtain the emergency IND prior to transfusion of the unit if your facility is not under a traditional IND or the expanded access program through Mayo Clinic. This is not needed prior to distribution of the unit from Vitalant to your hospital.
How does a non-contracted hospital obtain convalescent plasma from Vitalant?
Non-contracted customers can reach out to Vitalant’s Inventory Management team at
ProductManagement@vitalant.org or to discuss potential convalescent plasma ordering.
Where can your organization get the most up-to-date information about convalescent plasma?
This website is where we will maintain up-to-date information about the convalescent plasma program. We will continue to send email communications with major updates and required actions but please use this webpage as a frequently-checked resource at your organization.
If your organization is interested in the emergency use of investigational COVID-19 convalescent plasma, we strongly recommend you visit the
FDA’s webpage regarding “Recommendations for Investigational COVID-19 Convalescent Plasma” for more information about how your facility should work directly with the FDA to prepare.
Who should I contact at Vitalant about its convalescent plasma program?
If you represent a facility that has interest/need to transfuse active COVID-19 patients please reach out to
your area’s Regional Account Manager and Medical Director with questions/inquiries.
For questions regarding reimbursement for CCP products under various INDs/programs, please reach out to your Vitalant contact.